What is the debt of MacroGenics this year?
MacroGenics has a debt level of -182.84 USD this year.
MacroGenics Debt 2025
MacroGenics Debt
-182.84 USD
Ticker
MGNX
ISIN
US5560991094
WKN
A1W6ND
In 2025, MacroGenics's total debt was -182.84 USD, a 81.11% change from the -100.96 USD total debt recorded in the previous year.
MacroGenics Aktienanalyse
What does MacroGenics do?
MacroGenics Inc is a biotechnology company that was founded in 2000 and is headquartered in Rockville, Maryland, USA. The company specializes in the research, development, and commercialization of therapeutic antibodies used in the treatment of cancer and autoimmune diseases. MacroGenics' business model is based on the production of different antibodies that primarily target various cell types and thereby elicit a targeted response. The company relies on a balanced approach to research and development to preferentially identify cellular markers that are characteristic of certain diseases, allowing for the identification of specific target molecules for antibody development. These innovative therapies lead to an improvement in the quality of life for patients by curing or at least managing severe diseases. Over the years, MacroGenics has built several divisions, including: Antibody platform technologies MacroGenics utilizes its proprietary platform technology for phage display and antibody manufacturing (Digitalis), as well as for the discovery of target molecules responsible for specific diseases. These technologies are used to identify new therapeutic antibody candidates and support the entire antibody development process. Cancer research and development MacroGenics is a pioneer in the development of innovative cancer therapies. One of the key products in this area is the antibody-based cancer drug Margetuximab, used for the treatment of metastatic breast cancer. Another promising drug in clinical phases is MGD019, which is highly effective for tumor treatment in the solid area. Autoimmune research and development MacroGenics is a leading developer of Neuromyelitis Optica Spectrum Disorder (NMOSD), which leads to recurring inflammation of the central nervous system. Additional products in the pipeline are being developed for the treatment of autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis, as there is still a wide range of needs in this field. Polyclonals and biosimilars This area includes the production of antibody polypeptides and biosimilar drugs. Antibody polypeptides can be used to treat infectious diseases or diagnose diseases. Biosimilar drugs are biological drugs that have similar active ingredients to other already approved drugs and are approved by the US Food and Drug Administration (FDA). These drugs are also known as generic replicas. MacroGenics' products have proven to be safe and effective in clinical trials. The company has established an extensive network of collaborations to market and distribute its products. Partners include major pharmaceutical companies such as Pfizer, Servier, and Janssen Biotech. Overall, MacroGenics has over 20 product pipelines in various stages of development and is constantly working to expand its product pipelines. The company employs over 400 employees and aims to revolutionize the treatment of severe and life-threatening diseases. In conclusion, MacroGenics Inc is an innovative biotechnology company that has developed and designed a variety of products for the treatment of cancer and autoimmune diseases. The company has a wide range of proprietary platform technologies and is constantly striving to expand its product pipelines. We expect the company to continue growing in the coming years and harness its innovative power to further benefit patients. MacroGenics ist eines der beliebtesten Unternehmen auf Eulerpool.com.Debt Details
Understanding MacroGenics's Debt Structure
MacroGenics's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.
Year-to-Year Comparison
Analyzing MacroGenics's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.
Impact on Investments
Investors pay close attention to MacroGenics’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.
Interpreting Debt Fluctuations
Shifts in MacroGenics’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.
Frequently Asked Questions about MacroGenics stock
What was the debt of MacroGenics compared to the previous year?
The debt of MacroGenics has increased by 81.11% compared to the previous year increased.
What are the consequences of high debt for investors in MacroGenics?
High debt can pose a risk for investors of MacroGenics, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.
What are the consequences of low debt for investors of MacroGenics?
Low debt means that MacroGenics has a strong financial position and is able to fulfill its obligations without overburdening its finances.
How does an increase in debt from MacroGenics affect the company?
An increase in debt of MacroGenics can adversely affect the financial condition of the company and result in a higher burden on its finances.
How does a reduction of debt of MacroGenics affect the company?
A reduction in debt of MacroGenics can strengthen the company's financial position and improve its ability to meet its financial obligations.
What are some factors that influence the debt of MacroGenics?
Some factors that can influence the debt of MacroGenics include investments, acquisitions, operating costs, and revenue development.
Why are the debts of MacroGenics so important for investors?
The debts of MacroGenics are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.
What strategic measures can MacroGenics take to change the debt?
To change the debt, MacroGenics can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.
How much dividend does MacroGenics pay?
Over the past 12 months, MacroGenics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, MacroGenics is expected to pay a dividend of 0 USD.
What is the dividend yield of MacroGenics?
The current dividend yield of MacroGenics is .
When does MacroGenics pay dividends?
MacroGenics pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of MacroGenics?
MacroGenics paid dividends every year for the past 0 years.
What is the dividend of MacroGenics?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is MacroGenics located?
MacroGenics is assigned to the 'Health' sector.
Wann musste ich die Aktien von MacroGenics kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of MacroGenics from 10/7/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/7/2025.
When did MacroGenics pay the last dividend?
The last dividend was paid out on 10/7/2025.
What was the dividend of MacroGenics in the year 2024?
In the year 2024, MacroGenics distributed 0 USD as dividends.
In which currency does MacroGenics pay out the dividend?
The dividends of MacroGenics are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The MacroGenics stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von MacroGenics
Our stock analysis for MacroGenics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of MacroGenics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
